FDA News

FDA Update

August 2014, Vol 4, No 5 - FDA News

Ofatumumab Approved for Chronic Lymphocytic Leukemia The US Food and Drug Administration approved ofatumumab (Arzerra Injection, GlaxoSmithKline) in combination with chlor­ambucil, for the treatment of previously untreated patients with chronic lymphocytic leukemia, for whom fludarabine-based therapy is considered inappropriate. The [ Read More ]

FDA Update

May 2014, Vol 4, No 3 - FDA News

Zykadia Approved for Metastatic, ALK-Positive Lung Cancer On April 29, 2014, the US Food and Drug Administration (FDA) approved ceritinib (Zykadia; Novartis) for the treatment of patients with metastatic, anaplastic lymphoma kinase (ALK)-positive non–small-cell lung cancer (NSCLC). Ceritinib is an [ Read More ]

FDA Update

March 2014, Vol 4, No 2 - FDA News

First Drug Combination Approved for Unresectable or Metastatic Melanoma The US Food and Drug Admin­istration (FDA) approved the use of dabrafenib (Tafinlar; GlaxoSmith­Kline) plus trametinib (Mekinist; GlaxoSmithKline) as a new combination therapy for the treatment of patients with advanced melanoma [ Read More ]

New Drug Update

October 2013, Vol 3, No 6 - FDA News

As oncology practice managers assume higher levels of assistance to the medical oncology staff, it becomes critically important to stay abreast of the latest news and updates concerning the drug agents used in cancer treatment. The following drugs have been [ Read More ]